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In steric exclusion chromatography (SXC), a crude sample is mixed with polyethylene glycol (PEG) and fed onto 
a single-use cellulose column. In this operation, selectivity is influenced strongly by the target species’ size, so 
SXC is well suited for purification of virus particles. The purified product is recovered at physiological pH and 
conductivity. We have observed recoveries above 95% for several cell culture-based virus particles used as viral 
gene transfer vectors or as viral vaccines, including: adeno-associated virus (AAV), Modified Vaccinia Ankara 
(MVA) virus, influenza virus, and yellow fever virus. Preliminary data for purification of lentiviruses suggests 
recoveries exceeding 60%. Host cell DNA and protein depletion are typically above 90% and infectivity is not 
compromised thanks to the inert character of PEG towards biomolecules and the mild elution conditions. 
 
Several AAV serotypes and display mutants were produced using HEK cells and purified with up to 95% 
recovery. Elution fractions had ≤2×1014 viral genomes·L−1 and, depending on the specific AVV particle, the 
purified viruses successfully transduced or induced gene knockdown in vitro. Elution pools from MVA virus 
produced in continuous bioreactors with an avian cell line contained about 3.7×109 infectious virions measured 
by TCID50. For influenza virus, four strains were produced in MDCK cells. Full recovery of all strains was 
observed using identical SXC conditions for both infectious and chemically inactivated viruses. The column 
capacity in terms of the viral hemagglutinin antigen was > 50 mg·m−2. In the case of yellow fever virus, two 
attenuated strains were produced in Vero cells. Here, full recovery of infective titers was also achieved: the 
elution fraction was concentrated more than 100-fold to a titer of >6×109 plaque forming units (≈100 000 doses).  
 
In summary, SXC capture with PEG and unmodified cellulose membranes seems to perform very well for a 
broad range of viruses from different production processes. Thanks to the high degree of success in a relatively 
narrow operational range, SXC can drastically reduce process development. The high recoveries obtained so 
far, enable subsequent polishing operations with minimum risk to low overall process yields. 
 
